Skip to search formSkip to main contentSkip to account menu

SNX 2112

Known as: SNX-2112, SNX2112 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Heterocyclic Compounds, 4 or More Rings

Narrower (1)

PF 04928473

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Proteomic analysis of proteome and histone post-translational modifications in heat shock protein 90 inhibition-mediated bladder cancer therapeutics
Heat shock protein 90 (HSP90) inhibition is an attractive strategy for cancer treatment. Several HSP90 inhibitors have shown… 
2014
2014
Phase I dose-escalation studies of SNX-5422, an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumours.
2012
2012
Anti-herpes simplex virus efficacies of 2-aminobenzamide derivatives as novel HSP90 inhibitors.
2012
2012
The heat shock protein 90 inhibitor SNX-2112 inhibits B16 melanoma cell growth in vitro and in vivo.
SNX-2112 is a selective heat shock protein 90 (Hsp90) inhibitor which can exert a potent anticancer activity. In this… 
Highly Cited
2011
Highly Cited
2011
A Phase I Study of PF-04929113 (SNX-5422), an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Patients with Refractory Solid Tumor Malignancies and Lymphomas
Purpose: To determine the maximum tolerated dose (MTD), toxicities, and pharmacokinetic/pharmacodynamic profile of the Hsp90… 
2011
2011
SNX-2112, a Novel Hsp90 Inhibitor, Induces G2/M Cell Cycle Arrest and Apoptosis in MCF-7 Cells
SNX-2112 is a heat shock protein 90 (Hsp90) inhibitor with anticancer properties currently in clinical trials. This study… 
2011
2011
Antitumor Activity of SNX-2112, a Synthetic Heat Shock Protein-90 Inhibitor, in MET-Amplified Tumor Cells with or without Resistance to Selective MET Inhibition
Purpose: Heat shock protein-90 (HSP-90), a molecular chaperone required by numerous oncogenic kinases [e.g., HER-2, epidermal… 
Highly Cited
2009
Highly Cited
2009
Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents.
A novel class of heat shock protein 90 (Hsp90) inhibitors was developed from an unbiased screen to identify protein targets for a… 
Highly Cited
2008
Highly Cited
2008
SNX2112, a Synthetic Heat Shock Protein 90 Inhibitor, Has Potent Antitumor Activity against HER Kinase–Dependent Cancers
Purpose: The heat shock protein 90 (Hsp90) chaperone plays an important role in transformation by regulating the conformational… 
2008
2008
A Phase 1 dose-escalation study of the safety and pharmacokinetics (PK) of the oral Hsp90 inhibitor SNX-5422
14613 Background: SNX-5422 is an oral pro-drug of SNX-2112, a potent and highly selective small-molecule inhibitor of the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)